Neuroinflammation and Microglia Pathway in Alzheimer's Disease

Neuroinflammation and Microglia Pathway in Alzheimer's Disease

Overview

Neuroinflammation is a central pathological feature of Alzheimer's disease (AD), involving chronic activation of microglia, astrocytes, and the complement system [@heneka2015]. While neuroinflammation was originally considered a secondary response to amyloid and tau pathology, increasing evidence suggests it plays a primary role in disease progression. This page focuses on microglial-mediated neuroinflammation in AD [@wang2015].

Microglia in AD

Normal Microglial Function

Microglia are the resident immune cells of the CNS [@hansen2018]:

| Function | Mechanism | AD Relevance |
|----------|-----------|--------------|
| Surveillance | Continuous process extension | Impaired in AD |
| Phagocytosis | Clearance of debris/pathogens | Reduced in AD |
| Synaptic pruning | Complement-mediated | Excessive in AD |
| Cytokine release | Innate immune response | Dysregulated in AD |

Microglial States

Microglia adopt different activation states in AD [@keren2017]:

TREM2-Dependent Microglial Response

TREM2 Biology

TREM2 (Triggering Receptor Expressed on Myeloid Cells 2) is a microglial receptor critical for AD:

• Ligands: Aβ oligomers, lipoproteins, apoptotic cells
• Signaling: DAP12 adaptor protein
• Function: Phagocytosis, survival, cytokine production

Neuroinflammation and Microglia Pathway in Alzheimer's Disease

Overview

Neuroinflammation is a central pathological feature of Alzheimer's disease (AD), involving chronic activation of microglia, astrocytes, and the complement system [@heneka2015]. While neuroinflammation was originally considered a secondary response to amyloid and tau pathology, increasing evidence suggests it plays a primary role in disease progression. This page focuses on microglial-mediated neuroinflammation in AD [@wang2015].

Microglia in AD

Normal Microglial Function

Microglia are the resident immune cells of the CNS [@hansen2018]:

| Function | Mechanism | AD Relevance |
|----------|-----------|--------------|
| Surveillance | Continuous process extension | Impaired in AD |
| Phagocytosis | Clearance of debris/pathogens | Reduced in AD |
| Synaptic pruning | Complement-mediated | Excessive in AD |
| Cytokine release | Innate immune response | Dysregulated in AD |

Microglial States

Microglia adopt different activation states in AD [@keren2017]:

TREM2-Dependent Microglial Response

TREM2 Biology

TREM2 (Triggering Receptor Expressed on Myeloid Cells 2) is a microglial receptor critical for AD:

• Ligands: Aβ oligomers, lipoproteins, apoptotic cells
• Signaling: DAP12 adaptor protein
• Function: Phagocytosis, survival, cytokine production

DAM (Disease-Associated Microglia)

TREM2 Variants

Common AD risk variants in TREM2 [@guerreiro2013]:

• R47H: Increased AD risk (~3x)
• R62H: Modest risk increase
• D87N: Rare variant
• Y38C: Rare pathogenic

Complement System in AD

Complement Activation

The complement system is highly activated in AD:

Classical pathway:

• C1q binds to Aβ plaques
• Initiates cascade
• Generates C3a, C5a (anaphylatoxins)

• Microglial activation
• Synaptic elimination
• Inflammation amplification

C1q and Synaptic Pruning

C1q marks synapses for elimination:

Inflammatory Cytokines in AD

Key Cytokines

| Cytokine | Source | Effect in AD |
|----------|--------|--------------|
| IL-1β | Microglia, astrocytes | Pro-inflammatory, drives tau pathology |
| TNF-α | Microglia | Neurotoxic, synaptic dysfunction |
| IL-6 | Various | Acute phase, cognitive decline |
| IL-10 | Anti-inflammatory | Often elevated, may be compensatory |

Cytokine Signaling Pathways

Aβ plaques → Microglial activation → NF-κB activation → Pro-inflammatory cytokine release → Neuronal dysfunction

Astrocyte Involvement

Reactive Astrocytes

Astrocytes become reactive in AD:

• A1 astrocytes: Neurotoxic, induced by IL-1α, TNF, C1q
• Loss of function: Impaired glutamate uptake, potassium buffering
• Gain of function: Pro-inflammatory cytokine release

Astrocyte-Microglial Interactions

Cross-talk between astrocytes and microglia:

Neuroinflammation-Tau Interaction

Bidirectional Relationship

Tau pathology and neuroinflammation interact:

Microglial Phagocytosis of Tau

• Impaired clearance in AD
• Tau aggregates overwhelm microglia
• Failed degradation leads to inflammation

Therapeutic Approaches

Anti-Inflammatory Strategies

| Target | Approach | Agent | Status |
|--------|----------|-------|--------|
| NSAIDs | COX inhibition | Various | Failed |
| TREM2 | Agonistic antibodies | Anti-TREM2 mAbs | Phase 2 |
| IL-1β | Receptor antagonist | Anakinra | Phase 2 |
| Complement | C1q inhibition | Anti-C1q | Preclinical |

Microglial Modulation

| Strategy | Target | Status |
|----------|--------|--------|
| TREM2 activation | TREM2 | Phase 2 |
| Colony-stimulating factor 1 receptor (CSF1R) antagonism | Microglial depletion | Preclinical |
| PPARγ agonists | Anti-inflammatory | Failed |

Clinical Trials

| Trial ID | Intervention | Population | Status |
|----------|--------------|------------|--------|
| NCT01608142 | Anakinra | Mild AD | Completed |
| NCT02474948 | RG7412 (anti-TREM2) | AD | Phase 1 complete |
| NCT05618348 | Tocilizumab | Early AD | Recruiting |
| NCT04881253 | Anti-TREM2 mAb | MCI-AD | Phase 2 |

Biomarkers

Inflammatory Markers

| Marker | Fluid | Correlation |
|--------|-------|-------------|
| YKL-40 | CSF, plasma | Disease progression |
| IL-6 | CSF | Cognitive decline |
| TNF-α | CSF | Disease severity |
| C1q | CSF | Synaptic loss |
| sTREM2 | CSF | TREM2 pathway engagement |

See Also

• [TREM2 pathway](/mechanisms/trem2-microglia-pathway-alzheimers)
• [Complement system](/mechanisms/complement-system-pathway)
• [Neuroinflammation overview](/mechanisms/neuroinflammation-pathway)
• [Alzheimer's disease](/diseases/alzheimers)
• [TREM2 gene](/genes/trem2)

References

Related Hypotheses

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

• [Blood-Brain Barrier SPM Shuttle System](/hypothesis/h-959a4677) — <span style="color:#81c784;font-weight:600">0.75</span> · Target: TFRC
• [Senescent Microglia Resolution via Maresins-Senolytics Combination](/hypothesis/h-3f02f222) — <span style="color:#81c784;font-weight:600">0.72</span> · Target: BCL2L1
• [Microglial Efferocytosis Enhancement via GPR32 Superagonists](/hypothesis/h-470ff83e) — <span style="color:#81c784;font-weight:600">0.63</span> · Target: CMKLR1
• [Circadian-Gated Maresin Biosynthesis Amplification](/hypothesis/h-83efeed6) — <span style="color:#81c784;font-weight:600">0.60</span> · Target: ALOX12
• [Astrocytic Lipoxin A4 Pathway Restoration via ALOX15 Gene Therapy](/hypothesis/h-ac55ff26) — <span style="color:#ffd54f;font-weight:600">0.58</span> · Target: ALOX15
• [Oligodendrocyte Protectin D1 Mimetic for Myelin Resolution](/hypothesis/h-f71a9791) — <span style="color:#ffd54f;font-weight:600">0.57</span> · Target: GPR37
• [Mitochondrial SPM Synthesis Platform Engineering](/hypothesis/h-13bbfdc5) — <span style="color:#ffd54f;font-weight:600">0.47</span> · Target: ALOX5

Related Analyses:

• [Immune atlas neuroinflammation analysis in neurodegeneration](/analysis/SDA-2026-04-02-gap-immune-atlas-neuroinflam-20260402) &#x1f504;
• [Neuroinflammation resolution mechanisms and pro-resolving mediators](/analysis/SDA-2026-04-01-gap-014) &#x1f504;

Pathway Diagram

The following diagram shows the key molecular relationships involving Neuroinflammation and Microglia Pathway in Alzheimer's Disease discovered through SciDEX knowledge graph analysis: